N4 Pharma PLC - London-headquartered pharmaceutical company - Optimisation programme delayed as DNA loading optimisation takes longer than expected with work still ongoing. N4 Pharma collaborating with Nanomerics at UCL School of Pharmacy, with Nanomatrics to start gradual return to laboratories from Monday next week. Evotec International Gmbh on track with in vitro testing of N4 Pharma's Nuvec vaccine delivery system in Covid-19. Recent work on Nuvec suggests it might have "a significant competitive advantage" as a possible oral vaccine delivery system due to its "unique spiky structure".
Current stock price: 4.26 pence
Year-to-date change: up 58%
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
N4 Pharma Plc (N4P)